The aim of this study was to evaluate the efficacy of PG102 at lowering levels of total IgE in asymptomatic subjects with atopy.

Inclusion Criteria:

• subjects who have atopy but no allergy-related symptoms
• subjects with total IgE levels of 300IU/ml or more
• acquisition of written informed consent prior to commencement of study
• no serious clinical symptoms and normal laboratory test results; in case of abnormal finding, subjects whose conditions are not deemed severe from the judgement of investigators

Exclusion Criteria:

• individuals with normal levels of total serum IgE
• ue of one or more allergic drugs
• serious clinical conditions (such as malignancies, severe cardiovascular disease etc.)
• serious mental disorder
• pregnant woman or woman of childbearing potential within 3 months
• subjects who participated in other clinical trials in the past 6months
• individuals who have a plan to participate in another clinical trials during this trial
• subjects with a history of kiwi allergy
• subjects whose conditions are inappropriate by investigators